Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or mRNA COVID-19 Vaccines

NCT07051031 is registered in ClinicalTrials.gov with Marcel Curlin as lead sponsor.

NCT NCT07051031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07051031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or mRNA COVID-19 Vaccines
Lead sponsor
Marcel Curlin
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 1, 2025
Completion date
June 14, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19